Rigel Pharmaceuticals Provides Update on COVID-19 Program
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that...
Source: prnewswire.com
📰 Clinical Development Program News
Page 11 - Clinical Development Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Development Program. Real-time updates on events, politics, business and more.
Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin),...
Source: prnewswire.com
Alkermes Announces FDA Approval of LYBALVI for the Treatment of Schizophrenia and Bipolar I Disorder
-- New Oral Medication Offers Established Antipsychotic Efficacy of Olanzapine With Less Weight Gain -- -- Commercial Launch Planned for Fourth Quarter 2021 -- -- Company to Host Investor
United States Paul Gionfriddo Marisa Borgasano Sandy Coombs Eli Lilly American Psychiatric Association
Source: finanznachrichten.de
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved LYBALVI™ (olanzapine and samidorphan)...
Source: prnewswire.co.uk
Alkermes to Host Webcast With Expert Oncologist Panel to Discuss Data on Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
- Webcast to be Held at 4:00 p.m. ET on Friday, June 4 - DUBLIN, May 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will host a webcast and conference call
United States Valentina Boni Omid Hamid Sandy Coombs Sourojit Bhowmick American Society Of Clinical Oncology
Source: finanznachrichten.de
Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19
Home / Top News / Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19 Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19 Phase 3 trial to evaluate efficacy and safety of AT-527, an oral antiviral for treatment of patients with mild to moderate COVID-19 in outpatient setting BOSTON, April 29, 2021 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVI...
United States Jean Pierre Sommadossi Jonae Barnes Atea Pharmaceuticals Corporate Communications Atea Pharmaceuticals Inc
Source: forextv.com
Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting
- Two Posters to Include Data Updates From ARTISTRY-1 and ARTISTRY-2 Clinical Trials Evaluating Immuno-Oncology Candidate Nemvaleukin Alfa - DUBLIN, April 28, 2021 /PRNewswire/ -- Alkermes
United States Valentina Boni Omid Hamid Sandy Coombs Sourojit Bhowmick American Society Of Clinical Oncology
Source: finanznachrichten.de
Alkermes Initiates ARTISTRY-6 Trial of Nemvaleukin Alfa Monotherapy in Patients With Melanoma
Share this article Share this article DUBLIN, April 27, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-6, a global phase 2 trial evaluating the anti-tumor activity, safety and tolerability of nemvaleukin alfa (nemvaleukin) monotherapy in patients with melanoma who have been previously treated with anti-PD-(L)1 therapy. The study will evaluate intravenously administered (IV) nemvaleukin in patients with mucosal melanoma and subcutaneously administere...
United States Craig Hopkinson Sandy Coombs Sourojit Bhowmick Drug Administration Clinical Development Program
Source: prnewswire.co.uk
Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA in Patients With Platinum-Resistant Ovarian Cancer
(0) DUBLIN, April 7, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (a tradename of Merck & Co., Inc. Kenilworth, NJ, USA) for a planned phase 3 study to evaluate nemvaleukin alfa ("nemvaleukin", formerly referred to as ALKS 4230), Alkermes novel investigational engineered interleukin-2 (IL-2) variant immunotherapy, in combination with MSDs KEYTRUDA (pembrolizumab), in comparison to investiga...
Source: finanznachrichten.de
Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer
Share this article Share this article DUBLIN, April 7, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (a tradename of Merck & Co., Inc. Kenilworth, NJ, USA) for a planned phase 3 study to evaluate nemvaleukin alfa ("nemvaleukin", formerly referred to as ALKS 4230), Alkermes novel investigational engineered interleukin-2 (IL-2) variant immunotherapy, in combination with MSDs KEYTRUDA ® (pem...
Source: prnewswire.com